N Ikegaki
Overview
Explore the profile of N Ikegaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Teshiba R, Ikegaki N, Tang X, Naranjo A, London W, et al.
Br J Cancer
. 2015 Jun;
113(1):57-63.
PMID: 26035700
Background: MYCN amplification with subsequent MYCN protein overexpression is a powerful indicator of poor prognosis of neuroblastoma patients. Little is known regarding the prognostic significance of the homologous MYC protein...
2.
Eggert A, Grotzer M, Zuzak T, Ikegaki N, Zhao H, Brodeur G
Eur J Cancer
. 2001 Dec;
38(1):92-8.
PMID: 11750845
Deregulation of apoptosis has been implicated in the pathogenesis, spontaneous regression and treatment resistance of neuroblastoma. A newly recognised member of the tumour necrosis factor (TNF)-family of death receptors known...
3.
Tang X, Evans A, Zhao H, Cnaan A, Brodeur G, Ikegaki N
Med Pediatr Oncol
. 2001 Jul;
36(1):80-2.
PMID: 11464911
Background: The EPH family is the largest subfamily of receptor protein-tyrosine kinases, consisting of EPHA and EPHB subgroups. Ligands of EPH family receptors are called ephrins, which include ephrin-A and...
4.
Evans A, Kisselbach K, Liu X, Eggert A, Ikegaki N, Camoratto A, et al.
Med Pediatr Oncol
. 2001 Jul;
36(1):181-4.
PMID: 11464878
Background: The compound CEP-751 (KT-6587), a potent and selective inhibitor of the Trk family of tyrosine kinases, has been shown to inhibit the growth of human neuroblastoma (NB) xenografts in...
5.
Eggert A, Ikegaki N, Liu X, CHOU T, Brodeur G
Med Pediatr Oncol
. 2001 Jul;
36(1):108-10.
PMID: 11464858
Background: Favorable neuroblastomas frequently express high levels of the TrkA receptor, and these tumors have a propensity to either differentiate or regress, but the mechanisms responsible for these two fates...
6.
Eggert A, Grotzer M, Zuzak T, Wiewrodt B, Ho R, Ikegaki N, et al.
Cancer Res
. 2001 Mar;
61(4):1314-9.
PMID: 11245427
Disruption of apoptotic pathways may be involved in tumor formation, regression, and treatment resistance of neuroblastoma (NB). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in...
7.
Fan L, Iyer J, Zhu S, Frick K, Wada R, Eskenazi A, et al.
Cancer Res
. 2001 Feb;
61(3):1073-9.
PMID: 11221835
Neuroblastoma is the second most common solid malignancy of childhood. Enhanced expression of the amplified N-myc gene in the tumor cells may be associated with poor patient prognosis and may...
8.
Eggert A, Grotzer M, Ikegaki N, Zhao H, Cnaan A, Brodeur G, et al.
J Clin Oncol
. 2001 Feb;
19(3):689-96.
PMID: 11157019
Purpose: Neurotrophins and their receptors regulate the proliferation, differentiation, and death of neuronal cells, and they have been implicated in the pathogenesis and prognosis of neuroblastomas and medulloblastomas. Tyrosine kinase...
9.
Tang X, Zhao H, Robinson M, Cnaan A, LONDON W, Cohn S, et al.
Med Pediatr Oncol
. 2000 Dec;
35(6):656-8.
PMID: 11107140
Background: EPH family receptor tyrosine kinases and their ligand ephrins play pivotal roles in development. High-level expression of transcripts encoding EPHB6 receptors (EPHB6), its ligands ephrin-B2 and ephrin-B3 (EFNB2, EFNB3)...
10.
Eggert A, Ho R, Ikegaki N, Liu X, Brodeur G
Med Pediatr Oncol
. 2000 Dec;
35(6):623-7.
PMID: 11107132
Background: Expression of the neurotrophin receptor TrkA is associated with a favorable prognosis in neuroblastoma (NB) and promotes growth inhibition and neuronal differentiation. Aggressive, MYCN-amplified NB tumors express little or...